Small case control analysis with 15 probiotics patients and 15 contol patients, showing no significant differences. PCR tests were only done weekly. Dosage is unknown. 115/LOE/301.4.2/IX/2020.The immune effects of probiotics are strain-specific.
This study is excluded in the after exclusion results of meta
analysis:
the observered difference in duration could be caused by the baseline difference in Ct values.
Abstract: Indian Journal of Forensic Medicine & Toxicology, April-June 2021, Vol. 15, No. 2
4021
Probiotics Intake as Adjunct Therapy for Infected Health-Care
with SARS COV-2
Anna Surgean Veterini1, Eighty Mardiyan Kurniawati2, Hamzah3, Subijanto Marto Soedarmo4,
Cita Rosita Sigit Prakoeswa5, Damayanti Tinduh6
1Anesthesiologist
Intensivist, 2Obstetrician, 3Anesthesiologist Intensivist, 4Prof., Pediatrician,
5
Prof. Dermatologist, 6Medical Rehabilition Specialist of Dr Soetomo General Academic Hospital – Universitas
Airlangga, Address: Jalan Prof. Dr. Moestopo 6-8 Surabaya, Indonesia
Abstract
Objectives: We performed this case-control observational study to evaluate the comparison of the length of
duration of SARS COV-2 infection and the cycle threshold (Ct) value of reverse-transcriptase polymerase
chain reaction (RT-PCR) nasopharynx swab between the probiotics intake (case) group and the nonprobiotics intake (control) group.
Materials and Methods: Our study was a case-control study involving 15 cases and 15 controls match
for RT-PCR positive results. The participants were healthcare consisted of registrars, consultants, and
nurses. Each participant was interviewed by google forms using a structured questionnaire to collect sociodemographic characteristics, diet, therapy from a pulmonologist, and adjunct therapy.
Results: The total participants consisted of 15 males and 15 females. 4 participants in the case group had
febrile, 1 participant with anosmia, 1 participant with febrile, nausea, and vomit before they consumed
probiotics, and 9 participants without clinical complaints. One participant in the control group had fevered
and cough, 14 participants without clinical complaints—1 participant with co-morbidities in the control
group. The data of age, duration of infection, and cycle threshold (Ct) value were in the normal distribution.
Analysis results using SPSS 21.00 show no significant differences in the course of disease between the case
group and the control group. We found 2 participants in the control group had re-infection, while there was
no re-infection in the case group.
Conclusion: The present study’s finding may imply future care for the viral infection through the
immunomodulation mechanism by probiotics consumption.
Keywords: Probiotics; Immunomodulator; COVID-19
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.